medi-6469
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2013 (NCT01862900)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFRSF4 agonist
TNFSF4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109531 ↗
Also known as
- medi6469
- medi-6469
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02559024 | Phase 1 | Sep 1, 2015 | MedImmune, Providence Health & Services |
| NCT02205333 | Phase 1/Phase 2 (Phase 2) | Aug 13, 2014 | MedImmune |
| NCT01862900 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2013 | MedImmune, Providence Health & Services, Robert W. Franz Cancer Center |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 3 | 1 | 2 | 2013 |
| Providence Health & Services | Academic/Hospital | 2 | 2 | 2 | 2013 |
| Robert W. Franz Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1